The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Immunomedics; Janssen; Janssen (Inst); Loxo/Lilly; MSD Oncology; MSD Oncology (Inst); Pfizer/EMD Serono; Roche; Seagen; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Nobuaki Matsubara
Honoraria - Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
 
Se Hoon Park
Honoraria - Merck; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Janssen Oncology
Research Funding - Ono Pharmaceutical; Sanofi
 
Robert A Huddart
Leadership - Cancer clinic london Limited liability partnership
Consulting or Advisory Role - Bayer; Gilead Sciences; Janssen Oncology; Merck Sharp & Dohme; Nektar; Roche
Speakers' Bureau - Bristol Myers Squibb Foundation; Pfizer
Research Funding - Astellas Pharma (Inst); Basilea (Inst); Bristol-Myers Squibb (Inst); Immunomedics (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for dug discovery from Janssen (Inst)
Travel, Accommodations, Expenses - Nektar; Roche/Genentech
 
Earle F Burgess
Stock and Other Ownership Interests - Arvinas; Becton Dickinson; Calithera Biosciences; Exelixis; Gilead Sciences; Macrogenics; Medtronic
Honoraria - Exelixis; Janssen Oncology; Merck; Novartis; Pfizer
Consulting or Advisory Role - Johnson & Johnson
Speakers' Bureau - AstraZeneca; Exelixis
Research Funding - Astellas Pharma; Pfizer
 
Nadine Houede
No Relationships to Disclose
 
Severine Banek
Honoraria - Janssen
 
Brigitte Laguerre
Travel, Accommodations, Expenses - Astellas Pharma; Janssen; Pfizer
 
Valentina Guadalupi
Research Funding - Ipsen
 
Ja Hyeon Ku
No Relationships to Disclose
 
Spyros Triantos
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Sydney Akapame
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Kris Deprince
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Sutapa Mukhopadhyay
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Arlene O. Siefker-Radtke
Honoraria - Janssen
Consulting or Advisory Role - AstraZeneca; Bavarian Nordic; Bristol-Myers Squibb; G1 Therapeutics; Genentech; Gilead Sciences; IDEAYA Biosciences; Janssen; Loxo; Merck; Mirati Therapeutics; Nektar; Seagen; Taiho Oncology
Research Funding - Basilea Pharmaceutical; Bristol-Myers Squibb; Janssen; Merck; Millennium; Mirati Therapeutics; Nektar